Mustang Bio, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
MBIO Nasdaq 2836 www.mustangbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Mustang Bio, Inc.

Cascade Prodrug Inc. Appoints Industry Veterans Manuel (Manny) Litchman and Andres Gutierrez to Board of Directors - Aug 28th, 2025 3:19 pm
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma - Jul 7th, 2025 6:30 am
Wall Street Set to Open Lower Wednesday as Jobs Data Misses Forecasts - Jul 2nd, 2025 7:13 am
Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement - Mar 5th, 2025 2:15 pm
Mustang Bio Announces Sale of Fixed Assets and Exit of Facility - Feb 27th, 2025 2:05 pm
Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement - Feb 11th, 2025 2:10 pm
Mustang Bio Announces Closing of $8 Million Public Offering - Feb 10th, 2025 6:00 am
Mustang Bio Announces Pricing of $8 Million Public Offering - Feb 6th, 2025 5:00 am
Mustang Bio Announces Reverse Stock Split - Jan 14th, 2025 6:00 am